Three decades of progress against tuberculosis are now at serious risk of reversal. With global health funding contracting and drug-resistant strains proving stubbornly persistent, this landmark GBD 2023 analysis arrives at a moment when the world's trajectory toward the WHO End TB targets has never been more uncertain — and the data offer both cautious encouragement and stark warning in equal measure.
Drawing on vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling data across 204 countries and territories from 1990 to 2023, the analysis deployed Cause of Death Ensemble modelling and DisMod-MR 2.1 to simultaneously estimate TB incidence, prevalence, and mortality stratified by HIV status and drug-resistance profile. Disability-adjusted life-years were calculated to capture both fatal and non-fatal burden. A comparative risk assessment framework quantified how much of the TB burden is attributable to alcohol use, smoking, and elevated fasting plasma glucose — modifiable risks that rarely receive adequate attention in TB control strategies. The WHO End TB Strategy demands a 95% reduction in TB deaths and a 90% reduction in incidence between 2015 and 2035, targets that the study evaluates with granular regional disaggregation.
What this analysis ultimately reveals is that TB mortality has declined meaningfully since 1990, driven substantially by HIV program integration and improved case detection, yet multidrug-resistant TB represents a qualitatively different and under-addressed threat. MDR-TB is not simply more TB — it fractures the treatment paradigm that underpins all incidence projections. The inclusion of metabolic and behavioral risk factors marks a meaningful analytical evolution: tuberculosis has long been framed as a poverty disease, but the GBD data suggest modifiable lifestyle factors contribute independently to burden in middle-income settings. The study's primary limitation is its dependence on modeling in high-burden, low-surveillance regions where data quality remains uneven. Still, as a pre-disruption baseline, this analysis is likely the most comprehensive accounting of global TB burden available — and its timing, just as funding retreats, makes it analytically and politically essential reading.